ClinicalTrials.gg
CompletedNCT02735122Updated Sep 28, 2022

Study of Acetaminophen (ACM) in Post-operative Dental Pain

A Phase 3 interventional study of acetaminophen Tablet and acetaminophen Caplet in Post Operative Dental Pain, sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Completed at 1 site in United States. Open to participants aged 17 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-09-28.

Sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division (formerly part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2016, 10 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2017.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
17 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
9th of 137
420 · median 95
Started
2016
with 8 others
Phase 3
22 of 137
none open now
Registered
91st of 137
by date

Among the 137 studies testing acetaminophen in Pain, this one is the 9th largest by enrollment, is one of 9 that started in 2016, is one of 22 in phase 3, and was the 91st registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 17 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

This is a Dental Pain Study which will evaluate the analgesic onset, efficacy and safety of 1000 mg acetaminophen as two Test acetaminophen 500 mg tablets, compared with commercial products of acetaminophen 1000 mg administered as two 500 mg caplets, and ibuprofen (IBU) 400 mg following third molar (wisdom tooth) extraction.

Read the detailed description

This is a single-dose, randomized, double-blind, triple-dummy, placebo- and active controlled, parallel-group study to evaluate the analgesic onset, efficacy, and safety profile of Test acetaminophen 1000 mg compared with two commercial products over a six-hour period after third-molar extractions. Subjects will undergo dental extraction of three or four third molars.

03

Conditions studied

  • Post Operative Dental Pain

Browse trials for

04

Who can participate

Ages eligible
17 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 17 years to 50 years old
  2. Weight 100 lbs or greater with a (BMI) 18-30 inclusive
  3. Dental extraction of three or four molars
  4. Experience moderate to severe pain after extraction of third molars
  5. Females of childbearing age must be willing to use acceptable method of

Exclusion criteria

Exclusion Criteria:

  1. Currently pregnant or planning to be pregnant or nursing a baby
  2. Known allergy to acetaminophen (ACM) or non-steroidal anti-inflammatory drugs (NSAIDS)
  3. Inability to swallow whole large tablets or capsules
  4. Have other conditions that the investigator feels may impact subject's safety and/or the integrity of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (actual)

Study arms

  • Experimental
    Test acetaminophen

    acetaminophen tablet and placebo caplet and placebo liquid-filled capsule

    Drug: acetaminophen Tablet · Drug: Placebo Caplet · Drug: Placebo Liquid-filled capsule

  • Active comparator
    Commercial acetaminophen

    acetaminophen caplet and placebo tablet and placebo liquid-filled capsule

    Drug: acetaminophen Caplet · Drug: Placebo Tablet · Drug: Placebo Liquid-filled capsule

  • Active comparator
    Commercial ibuprofen

    ibuprofen liquid-filled capsule and placebo tablet and placebo caplet

    Drug: ibuprofen Liquid-filled capsule · Drug: Placebo Tablet · Drug: Placebo Caplet

  • Placebo comparator
    Placebo

    Placebo tablet and placebo caplet and placebo liquid-filled capsule

    Drug: Placebo Tablet · Drug: Placebo Caplet · Drug: Placebo Liquid-filled capsule

Interventions

  • 2 test acetaminophen 500 mg tablets

    Also known as: Test ACM

  • Drugacetaminophen Caplet

    2 commercial acetaminophen 500 mg caplets

    Also known as: Commercial ACM

  • Drugibuprofen Liquid-filled capsule

    2 commercial ibuprofen 200 mg Liquid-filled capsules

    Also known as: Commercial IBU

  • DrugPlacebo Tablet

    2 placebo tablets

  • DrugPlacebo Caplet

    2 placebo caplets

  • DrugPlacebo Liquid-filled capsule

    2 placebo Liquid-filled capsules

06

What researchers measure

Primary outcomes

  1. Time to first confirmed perceptible pain relief

    Minutes until confirmed first perceptible pain relief are achieved. Stopwatch is started after the subject takes the study medication. The subject is instructed to stop the stopwatch when they first begin to feel any pain relief. The first perceptible pain relief is confirmed if the subject also stopped the second stopwatch indicating meaningful pain relief.

    Time frame: 6 hours

Secondary outcomes

  1. Percentage of subjects with confirmed perceptible relief from 30 minutes to successively earlier minutes in one-minute increments (Test ACM versus placebo)

    Time frame: 30 minutes or less

  2. Risk ratios of confirmed perceptible relief by 10 minutes (Test acetominophen and commercial ibuprofen)

    The risk ratios and confidence intervals for incidence of confirmed perceptible relief of Test ACM divided by commercial IBU will be presented for 10 minutes

    Time frame: 10 minutes or less

  3. Risk ratios of confirmed perceptible relief by 15 minutes (Test acetominophen and commercial ibuprofen)

    The risk ratios and confidence intervals for incidence of confirmed perceptible relief of Test ACM divided by commercial IBU will be presented for 15 minutes

    Time frame: 15 minutes or less

  4. Risk ratios of confirmed perceptible relief by 20 minutes (Test acetominophen and commercial ibuprofen)

    The risk ratios and confidence intervals for incidence of confirmed perceptible relief of Test ACM divided by commercial IBU will be presented for 20 minutes

    Time frame: 20 minutes or less

  5. Percentage of subjects with meaningful relief by 30 minutes

    Time frame: 30 minutes or less

  6. Time to meaningful pain relief

    Minutes until meaningful pain relief are achieved. Stopwatch is started after the subject takes the study medication. The subjects are instructed to stop the stopwatch when the relief from the starting pain is meaningful to them.

    Time frame: 6 hours

07

Study locations

1 site
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: Yes — At this time we do plan to share IPD through the YODA site. The specific individual participant data sets have not yet been determined.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Oct 2016, 5 months.

Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 5 months is below that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2016
First posted
Apr 12, 2016
StartActual
Apr 30, 2016
Primary completionActual
Oct 5, 2016
CompletionActual
Oct 5, 2016
Results delay requested
Oct 9, 2017
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02735122
Responsible party
Sponsor
First posted
Apr 12, 2016
Start date
Apr 30, 2016
Primary completion
Oct 5, 2016
Completion
Oct 5, 2016
Last update
Sep 28, 2022

Study contacts

Derek D. Muse, M.D.
principal investigator · Jean Brown Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion